about
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.The severity of irritable bowel syndrome or the presence of fibromyalgia influencing the perception of visceral and somatic stimuliThe effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis.Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies.Rehabilitation in psoriatic arthritis.Emerging drugs for psoriatic arthritis.Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis.Updated guidelines for the management of axial disease in psoriatic arthritis.Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.Measuring psoriatic disease in clinical practice. An expert opinion position paper.Trauma and seronegative spondylarthropathy.Simple clinical indicators for early psoriatic arthritis detection.Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up.Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia.Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis.Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis.Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.A novel biological target for the treatment of psoriatic arthritis.Beyond anti-TNF-α agents in psoriatic arthritis.Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation.Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis.The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices.Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.Unmet Needs in Axial Spondyloarthritis.An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment.Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder.Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients.Psoriatic arthritis and psoriasis projects in Italy: a report from the GRAPPA 2011 annual meeting.Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria.Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literatureWhat Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis?Role of comorbidities in spondyloarthritis including psoriatic arthritisRemission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study
P50
Q33387811-25350EA2-E310-4F7C-8D24-B8434D3941AAQ34887939-57B8A7B0-FF48-4535-9E78-9334AFDC705EQ35132212-BE5A75AB-CCD2-4B9A-AFDB-AE58586BD1A5Q36940942-6F1D0643-E6F3-45AD-80F8-4AFC406C0558Q37301177-B2D2CAEA-E471-4A8E-ABAB-7668D7B533EEQ37515034-96217D5F-AA06-42B4-AF0B-0E596271BB16Q37574765-CFD65EBA-3020-40BF-A98E-6A97CAC07E5FQ37763192-0653DDC2-88A7-473C-AA67-4481CA9E993FQ38177340-6D4D5AB9-9BB1-4D64-ADEF-911556E2CD3BQ38230867-A041F40E-FA28-4A7E-A913-44BB9B53712EQ38264282-B163B6E5-7E78-4011-93D8-492072E7D4CFQ38275675-E6C3492C-4392-4F5E-83EB-A46FF6119509Q38344512-14C75EF7-454C-487B-BE6E-7DD8DC18ABF2Q38508340-3A1385D3-BF62-432E-913E-B7A684CDBD8CQ41229919-C7FA36AE-194F-4A92-9FE9-AFB23A295FDBQ41446342-7048242C-4B26-491B-86E2-4DEEB4BC0637Q42450121-CF63C048-0D11-41FF-BA62-1D35707F1859Q42632287-2F9B350C-FE2A-4FFC-A242-16102509677AQ43295202-5E153C92-9477-4C2A-A2DA-E83173E99965Q43440017-D70C0EE8-AE04-4071-B2B1-3CE733A76F19Q43644152-1668A5E2-051B-46EA-8642-C4833B7F1C13Q43830758-D17C259A-EAB9-414B-BF4B-E0AC5A74F76BQ44268181-908FA11F-56C9-456E-80FE-51B8063F8DF5Q45093370-A710733D-E817-4B25-B23F-8280D5A8BE26Q46949484-146E7F71-D87E-405D-8F6B-BF4CD64567A9Q47287638-2EF6A9E8-4D46-4887-AA00-9DF8BC08E140Q47381622-9686B39A-820B-455B-853B-E85E7B193999Q47942295-96D684C8-6875-48EB-B86F-BD109C91435AQ47954115-A341C970-F273-4EC7-AED9-4C22ABC09485Q48287506-CF314532-0CEC-4663-B00E-D530F8E6B4DBQ48367391-AB80C713-9A2B-4EC8-8107-E11A23CD7DAFQ48685114-9500ACC0-2B98-4C5E-A45E-23C21BE09ED1Q51190165-05F807D1-3882-48A3-A929-4C79AA44EF7DQ51197471-BA8A1D77-A175-4A91-B787-136408C9F165Q51714523-30863E7A-3342-4DCF-8A78-0A2F2509034CQ52852865-341B1A61-159D-4AAA-AC47-4187BEADB338Q57062376-4EFEBB09-872A-4FD7-8AF4-0F6425B4A2E5Q58417462-8E41602D-F2D9-4527-90CB-349858A6927AQ58594482-4F81D981-44EE-4079-AD60-259CBB412727Q61633962-9E51B0EC-ADFD-4779-A9DA-DF2387A1A8F5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ennio Lubrano Di Scorpaniello
@ast
Ennio Lubrano Di Scorpaniello
@en
Ennio Lubrano Di Scorpaniello
@es
Ennio Lubrano Di Scorpaniello
@nl
Ennio Lubrano Di Scorpaniello
@sl
type
label
Ennio Lubrano Di Scorpaniello
@ast
Ennio Lubrano Di Scorpaniello
@en
Ennio Lubrano Di Scorpaniello
@es
Ennio Lubrano Di Scorpaniello
@nl
Ennio Lubrano Di Scorpaniello
@sl
altLabel
Ennio Lubrano
@en
prefLabel
Ennio Lubrano Di Scorpaniello
@ast
Ennio Lubrano Di Scorpaniello
@en
Ennio Lubrano Di Scorpaniello
@es
Ennio Lubrano Di Scorpaniello
@nl
Ennio Lubrano Di Scorpaniello
@sl
P106
P1153
6603342351
P21
P31
P496
0000-0001-6189-5328